State Street Corp increased its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 2.1% during the third quarter, according to its most recent filing with the SEC. The fund owned 37,103 shares of the company’s stock after buying an additional 758 shares during the quarter. State Street Corp owned 0.07% of Crispr Therapeutics worth $1,521,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics in the second quarter worth $5,165,000. River & Mercantile Asset Management LLP purchased a new position in Crispr Therapeutics in the second quarter worth $4,032,000. Finally, OZ Management LP bought a new position in Crispr Therapeutics in the second quarter valued at $3,876,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
CRSP opened at $59.90 on Friday. Crispr Therapeutics AG has a 1 year low of $29.34 and a 1 year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock’s 50 day simple moving average is $65.94 and its 200 day simple moving average is $51.65. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -17.41 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, sell-side analysts anticipate that Crispr Therapeutics AG will post 0.65 EPS for the current year.
A number of equities research analysts have weighed in on the company. Canaccord Genuity raised their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research report on Wednesday, November 20th. Chardan Capital reissued a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Monday, November 18th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Goldman Sachs Group increased their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Finally, TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $71.38.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Profit Margin
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.